LifeStance Health Group (LFST) Projected to Post Quarterly Earnings on Thursday

LifeStance Health Group (NASDAQ:LFST) is projected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect LifeStance Health Group to post earnings of $0.02 per share and revenue of $414.3750 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $403.48 million for the quarter, compared to the consensus estimate of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. LifeStance Health Group’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeStance Health Group Trading Down 3.4%

Shares of NASDAQ:LFST opened at $10.86 on Thursday. The company has a 50 day moving average of $9.53 and a 200-day moving average of $7.90. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4.21 billion, a P/E ratio of 181.00 and a beta of 1.12. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $11.76.

Insider Activity at LifeStance Health Group

In related news, Director Robert Bessler sold 894,337 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the sale, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Eric Shuey sold 243,362 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the sale, the director owned 867,562 shares of the company’s stock, valued at $6,957,847.24. The trade was a 21.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 7,687,394 shares of company stock valued at $63,579,701 over the last ninety days. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Several large investors have recently modified their holdings of LFST. Bayesian Capital Management LP acquired a new position in shares of LifeStance Health Group in the 2nd quarter valued at $52,000. Cibc World Markets Corp purchased a new position in LifeStance Health Group in the 4th quarter worth about $77,000. Qtron Investments LLC acquired a new stake in LifeStance Health Group during the 4th quarter worth about $83,000. Northwestern Mutual Wealth Management Co. raised its holdings in LifeStance Health Group by 569.1% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 12,024 shares of the company’s stock worth $85,000 after buying an additional 10,227 shares during the period. Finally, Orion Porfolio Solutions LLC purchased a new stake in LifeStance Health Group during the fourth quarter valued at about $88,000. 85.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on LFST. The Goldman Sachs Group began coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price on the stock. Wall Street Zen lowered LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. BTIG Research lifted their price target on LifeStance Health Group from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, KeyCorp upped their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.